CY1117302T1 - Αντισωματα αντι-mif - Google Patents
Αντισωματα αντι-mifInfo
- Publication number
- CY1117302T1 CY1117302T1 CY20151100250T CY151100250T CY1117302T1 CY 1117302 T1 CY1117302 T1 CY 1117302T1 CY 20151100250 T CY20151100250 T CY 20151100250T CY 151100250 T CY151100250 T CY 151100250T CY 1117302 T1 CY1117302 T1 CY 1117302T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mif
- antibodies
- relates
- antigen
- binding fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μονοκλωνικά αντισώματα και τμήματα αυτών δέσμευσης με αντιγόνο που δεσμεύονται ειδικά με το C-άκρο ή την κεντρική περιοχή του παράγοντα αναστολής της μετανάστευσης μακροφάγων (MIF). Τα εν λόγω αντισώματα αντι-MIF και τα τμήματα αυτών δέσμευσης με αντιγόνο επιπλέον αναστέλλουν τη βιολογική λειτουργία του ανθρωπίνου MIF. Η αίτηση αναφέρεται επίσης σε απομονωμένες ανοσοσφαιρίνες βαριάς και ελαφριάς αλυσίδας που προέρχονται από αντισώματα αντι-MIF και μόρια νουκλεϊνικών οξέων που κωδικοποιούν τέτοιες ανοσοσφαιρίνες. Η παρούσα αίτηση αναφέρεται επίσης σε μια μέθοδο ταυτοποίησης αντισωμάτων αντι-MIF, σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τα εν λόγω αντισώματα και μια μέθοδο χρήσης των εν λόγω αντισωμάτων και συνθέσεων για τη θεραπευτική αγωγή διαταραχών σχετικών με τον MIF.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1898808P | 2008-01-04 | 2008-01-04 | |
US9468508P | 2008-09-05 | 2008-09-05 | |
EP08869976.4A EP2231707B1 (en) | 2008-01-04 | 2008-12-30 | Anti mif antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117302T1 true CY1117302T1 (el) | 2017-04-26 |
Family
ID=40535633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100250T CY1117302T1 (el) | 2008-01-04 | 2015-03-13 | Αντισωματα αντι-mif |
Country Status (23)
Country | Link |
---|---|
US (3) | US20090220521A1 (el) |
EP (4) | EP2231707B1 (el) |
JP (1) | JP5502752B2 (el) |
KR (2) | KR101654678B1 (el) |
CN (2) | CN103724430B (el) |
AU (1) | AU2008346517B2 (el) |
BR (1) | BRPI0821682A2 (el) |
CA (1) | CA2711029A1 (el) |
CY (1) | CY1117302T1 (el) |
DK (1) | DK2231707T3 (el) |
ES (3) | ES2623653T3 (el) |
HK (1) | HK1147762A1 (el) |
HR (1) | HRP20150224T1 (el) |
IL (1) | IL206715A (el) |
MX (1) | MX2010007406A (el) |
NZ (3) | NZ611117A (el) |
PL (2) | PL3118223T3 (el) |
PT (1) | PT2231707E (el) |
RS (1) | RS53906B1 (el) |
RU (2) | RU2509777C2 (el) |
SI (1) | SI2231707T1 (el) |
WO (1) | WO2009086920A1 (el) |
ZA (1) | ZA201004973B (el) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2231707B1 (en) * | 2008-01-04 | 2014-12-24 | Baxter International Inc. | Anti mif antibodies |
US9238689B2 (en) | 2011-07-15 | 2016-01-19 | Morpho Sys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) |
AU2012320597C1 (en) | 2011-10-07 | 2015-10-15 | Baxalta GmbH | oxMIF as a diagnostic marker |
JP2014530361A (ja) * | 2011-10-07 | 2014-11-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | Cho−mif遺伝子およびタンパク質の特性評価およびその使用 |
AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
AU2013203957B9 (en) * | 2012-04-16 | 2015-10-15 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Glucocorticoids |
JP2015523572A (ja) | 2012-07-10 | 2015-08-13 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | 抗mif免疫組織化学法 |
EP2929348B1 (en) * | 2012-12-07 | 2017-05-10 | Baxalta GmbH | Anti-mif antibody cell migration assay |
US10613100B2 (en) * | 2014-01-03 | 2020-04-07 | Baxalta Incorporated | Anti-MIF immunohistochemistry |
WO2016026956A1 (en) | 2014-08-22 | 2016-02-25 | Baxalta GmbH | Detection of cho-mif contaminations |
EP3277718B1 (en) | 2015-03-31 | 2021-03-24 | Baxalta GmbH | Dosage regimen for anti-mif antibodies |
EP3298039A1 (en) | 2015-05-18 | 2018-03-28 | Baxalta GmbH | Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras |
US11098113B2 (en) | 2016-09-15 | 2021-08-24 | Vib Vzw | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
CN109868311B (zh) * | 2017-12-01 | 2023-10-20 | 上海市精神卫生中心 | Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用 |
JP2021526820A (ja) * | 2018-06-07 | 2021-10-11 | オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 癌治療のための抗oxMIF/抗CD3抗体 |
EP3757252B1 (en) | 2019-06-28 | 2022-03-30 | Walter Ag | A coated cutting tool |
CN115943160A (zh) | 2019-12-06 | 2023-04-07 | 翁科奥内研发有限责任公司 | 抗oxMIF/抗CD3双特异性抗体构建体 |
EP4222170B1 (en) | 2020-10-02 | 2024-03-20 | OncoOne Research & Development GmbH | Improved anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity |
AU2022218320A1 (en) | 2021-02-03 | 2023-07-27 | Oncoone Research & Development Gmbh | ANTI-oxMIF RADIOIMMUNOCONJUGATE |
WO2023031397A1 (en) | 2021-09-03 | 2023-03-09 | Oncoone Research & Development Gmbh | IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY |
WO2023133361A2 (en) * | 2022-01-10 | 2023-07-13 | Phenomic Ai | Anti-cthrc1 fusion proteins and methods of using the same |
CN114573693A (zh) * | 2022-04-25 | 2022-06-03 | 中国人民解放军陆军军医大学 | 一种听觉发育中免疫调节分子mif抗体制备方法 |
CN115814069B (zh) * | 2022-10-31 | 2023-07-21 | 四川大学华西医院 | Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6774227B1 (en) * | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
JPH0977799A (ja) * | 1995-09-13 | 1997-03-25 | Sapporo Immuno Diagnostic Lab:Kk | ヒト−マクロファージ遊走阻止因子(ヒト−mif)に対するモノクローナル抗体および該抗体を産生するハイブリドーマ |
DK1156823T3 (da) * | 1999-02-12 | 2009-01-19 | Scripps Research Inst | Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier |
US20030235584A1 (en) * | 2000-02-28 | 2003-12-25 | Kloetzer William S. | Method for preparing anti-MIF antibodies |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
EP2231707B1 (en) * | 2008-01-04 | 2014-12-24 | Baxter International Inc. | Anti mif antibodies |
-
2008
- 2008-12-30 EP EP08869976.4A patent/EP2231707B1/en active Active
- 2008-12-30 PL PL16183733T patent/PL3118223T3/pl unknown
- 2008-12-30 MX MX2010007406A patent/MX2010007406A/es active IP Right Grant
- 2008-12-30 DK DK08869976.4T patent/DK2231707T3/en active
- 2008-12-30 BR BRPI0821682-7A patent/BRPI0821682A2/pt not_active IP Right Cessation
- 2008-12-30 US US12/346,309 patent/US20090220521A1/en not_active Abandoned
- 2008-12-30 AU AU2008346517A patent/AU2008346517B2/en active Active
- 2008-12-30 PL PL08869976T patent/PL2231707T3/pl unknown
- 2008-12-30 CA CA2711029A patent/CA2711029A1/en not_active Abandoned
- 2008-12-30 CN CN201410037650.3A patent/CN103724430B/zh active Active
- 2008-12-30 ES ES14163839.5T patent/ES2623653T3/es active Active
- 2008-12-30 ES ES08869976.4T patent/ES2531629T3/es active Active
- 2008-12-30 EP EP14163839.5A patent/EP2754671B1/en active Active
- 2008-12-30 CN CN200880127872.7A patent/CN101983207B/zh active Active
- 2008-12-30 NZ NZ611117A patent/NZ611117A/en unknown
- 2008-12-30 EP EP20120189220 patent/EP2548890A1/en not_active Withdrawn
- 2008-12-30 WO PCT/EP2008/011146 patent/WO2009086920A1/en active Application Filing
- 2008-12-30 PT PT08869976T patent/PT2231707E/pt unknown
- 2008-12-30 ES ES16183733T patent/ES2791333T3/es active Active
- 2008-12-30 NZ NZ586600A patent/NZ586600A/en unknown
- 2008-12-30 KR KR1020107017306A patent/KR101654678B1/ko active IP Right Grant
- 2008-12-30 KR KR1020167023984A patent/KR20160105943A/ko not_active Application Discontinuation
- 2008-12-30 JP JP2010541032A patent/JP5502752B2/ja active Active
- 2008-12-30 RU RU2010132647/10A patent/RU2509777C2/ru active
- 2008-12-30 SI SI200831400T patent/SI2231707T1/sl unknown
- 2008-12-30 RS RS20150197A patent/RS53906B1/en unknown
- 2008-12-30 EP EP16183733.1A patent/EP3118223B8/en active Active
- 2008-12-30 NZ NZ596409A patent/NZ596409A/xx unknown
-
2010
- 2010-04-26 US US12/767,635 patent/US8668909B2/en active Active
- 2010-06-30 IL IL206715A patent/IL206715A/en active IP Right Grant
- 2010-07-14 ZA ZA2010/04973A patent/ZA201004973B/en unknown
-
2011
- 2011-02-21 HK HK11101702.4A patent/HK1147762A1/xx unknown
-
2013
- 2013-12-03 RU RU2013153592/10A patent/RU2013153592A/ru not_active Application Discontinuation
-
2014
- 2014-01-17 US US14/157,967 patent/US20150023978A1/en not_active Abandoned
-
2015
- 2015-02-26 HR HRP20150224TT patent/HRP20150224T1/hr unknown
- 2015-03-13 CY CY20151100250T patent/CY1117302T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117302T1 (el) | Αντισωματα αντι-mif | |
CY1120665T1 (el) | Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους | |
CY1120065T1 (el) | Ανθρωπινα αντισωματα για ton erbb 2 | |
CY1118845T1 (el) | Πρωτεϊνες συνδεσης αντιγονου υποδοχεα α il-17 | |
CY1122476T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι) | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
CY1124747T1 (el) | Ανθρωπινα αντισωματα σε pd-1 | |
CY1122366T1 (el) | Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1120626T1 (el) | Αντισωματα και αλλα μορια που δεσμευουν β7-η1 και pd-1 | |
CO6351802A2 (es) | Anticuerpos para ccr2 | |
CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
EA201291243A1 (ru) | Антитела против респираторно-синцитиального вируса (рсв) и способы их применения | |
BR112012003064B8 (pt) | anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo | |
CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
WO2008079246A3 (en) | Cd44 antibodies | |
CY1118665T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων | |
CY1123781T1 (el) | Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων | |
UA117364C2 (uk) | Похідні аматоксину | |
CY1119890T1 (el) | Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1 | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
CY1118046T1 (el) | Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου |